This site uses cookies for tracking and statistical purposes. Please read our privacy policy for more information.
Don't show this again
This site uses cookies for tracking and statistical purposes. Please read our privacy policy for more information.
Don't show this again
Rapid genetic test to identify CYP2C19 metaboliser status in a time critical setting
Detecting the MT-RNR1 gene variant can reduce the risk of antibiotic induced hearing loss in newborns with suspected sepsis
The Genedrive® System is a point of care molecular diagnostics platform that can rapidly detect, pathogens or genetic variants aligned to clinical outcome.
The Genedrive® CYP2C19 ID Kit is a rapid point of care test for CYP2C19 genotyping informing clinicians on metaboliser status ahead of treatment prescription.
Ahead of World Stroke Day, David Budd, CEO of genedrive plc, underscores the growing role of pharmacogenetics in personalised medicine and how its application can decrease the odds of secondary cerebrovascular disease.
The world's first point of care test to screen infants in an urgent care setting for a genetic variant that will cause life-long hearing loss when carriers of the variant are given aminoglycoside antibiotics. A genetic test to establish if a newborn baby is vulnerable to deafness if treated with a commonly used antibiotic has been recommended by NICE in draft guidance.
The publication confirms Genedrive® MT-RNR1 test's role in avoiding antibiotic related hearing loss in infants. An important step in the management of neonatal sepsis. The PALOH study demonstrates the ease of use and capability of the Genedrive® technology to deliver rapid genetic information in a very time sensitive acute care situation.
© 2016-25 genedrive plc